EGFR and cancer: Gene amplifications or mutations that cause alternative growth factor receptor signaling, e.g., signaling downstream of the human epidermal growth factor receptor (HER) family, hepatocyte growth factor (HGF)/c-Met or insulin-like growth factor 1 receptor (IGF1R), confer resistance of cancer cells to EGFR-targeted TKIs [30, 31].